Our latest articles
The new variant might be able to dodge one of the PCR tests authorised in the US, the FDA says.
Ingrezza could have some advantages over approved therapies, but a more important Huntington’s readout nears.
Trial design comes into focus as late-stage readouts loom for Sanofi, Roche and Astrazeneca.
The Canadian subsidiary claims success in its pivotal trial, though capacity restraints will limit the jab’s role for now.
Formal approval for Keytruda looks to make life difficult for some anti-PD-(L)1 latecomers.
Three of four lymphoma patients given ADI-001 go into remission, and Adicet soars 30%.
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
With phase 3 data approaching, it should soon become clear whether Bridgebio’s amyloidosis project really has an edge over Pfizer’s Vyndaqel.
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.
The group gets a long-awaited win in kidney disease, but sales potential is hard to call.